HEMATOLOGY

BV consolidation therapy to reinforce CR among high-risk post-auto HSCT patients with HL: A local case sharing

14 Nov 2022

A local case sharing: the emergence of BV-CHP as a breakthrough frontline treatment for sALCL

18 Jul 2022

Carfilzomib: Expert insight into the Asian real-world data and a local case sharing

14 Jul 2022

An equally efficacious and safe alternative: The once-weekly carfilzomib-based therapy

04 Apr 2022

Applying CAR T-cell therapy in hematological malignancies from clinical studies to the real-world practice

05 Feb 2022

Promising real-world evidence of all-oral triplet combination of ixazomib, lenalidomide, and dexamethasone (IRd) for the treatment of rrMM

05 Jan 2022

Bridging towards allogeneic stem-cell transplant with the early use of novel therapies in the relapsed/refractory acute lymphoblastic leukemia setting

12 Aug 2021

Balancing efficacy and cardiovascular safety in chronic lymphocytic leukemia with acalabrutinib

03 Aug 2021

The real-world use of ixazomib achieved stable disease for nearly 3 years, longer than in clinical trial

24 Mar 2021
Expert Insight View All

Carfilzomib: Expert insight into the Asian real-world data and a local case sharing

Carfilzomib-based therapies have been approved for the management of patients with relapsed/refractory multiple myeloma (rrMM) based on the positive results from 2 randomized clinical trials, namely ASPIRE and ENDEAVOR.1-5 Although the 2 trials showed remarkable clinical benefits of carfilzomib-based rrMM treatments, it was still unclear whether these results could translate into routine clinical practice since some patients might not be eligible for the trials. As such, a prospective real-world (RW) study was performed to evaluate the effectiveness of carfilzomib + dexamethasone (Kd) or carfilzomib + lenalidomide + dexamethasone (KRd) in the RW setting among the Asian population, hoping to provide additional insights into the efficacy-effectiveness gap.6 In an interview with Omnihealth Practice, Dr. Kong, Shun-yin Jacky shared his insight into the latest Asian RW data of carfilzomib and presented a clinical case to demonstrate the effectiveness of Kd in rrMM management in the local clinical setting.
14 Jul 2022
thumb

Dr. Kong, Shun-Yin Jacky

Specialist in Hematology and Hematological Oncology

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

Multiple myeloma (MM) is a plasma cell malignancy with approximately 150,000 new cases globally each year.1 In 2016, approximately 270 new cases were reported in Hong Kong.1 As the second most frequent hematological disease worldwide, MM accounts for 0.9% of all new cancer cases and 1.1% of all canc
31 Dec 2020
thumb

Dr. Wong, Siu-Ming Raymond

Head of Division of Haematology,
Department of Medicine & Therapeutics,
Faculty of Medicine,
The Chinese University of Hong Kong
Conference update View All
thumb

EHA 2022

JUNE 9-12 | VIRTUAL

Meeting highlight View All

An equally efficacious and safe alternative: The once-weekly carfilzomib-based therapy

HEMATOLOGY
04 Apr 2022
thumb

Dr. Keith Stewart

Professor of Medicine,
Director,
Princess MargarXet Cancer Centre
Vice President,
Cancer, University Health Network,
Toronto, Canada
case review View All

BV consolidation therapy to reinforce CR among high-risk post-auto HSCT patients with HL: A local case sharing

Despite the fact that Hodgkin’s lymphoma (HL) patients generally have very high cure rates of 70%-90% with frontline multi-agent chemotherapies, the battle against this hematological malignancy is still ongoing.1,2 About 20% of HL patients were found failure to stay in complete remission (CR) within a year after the initial frontline therapies, and required autologous hematopoietic stem cell transplantation (HSCT) for the improvement of long-term outcomes.1 Yet, autologous HSCT could only cure 50% of the high-risk patients, meaning that half of them still experience progressive disease after autologous HSCT.2 Enormous efforts have been made to address the unmet medical needs of these patients since the 1990s, but a breakthrough only came in 2015 when brentuximab vedotin (BV) was investigated and shown to be highly efficacious in consolidating CR among high-risk HL patients who had undergone autologous HSCT.2 In an interview with Omnihealth Practice, Dr. Chan, Hiu-Yan Kitty discussed the unmet medical needs of HL patients and presented a case to demonstrate the clinical benefits of BV consolidation therapy in the local clinical setting.
14 Nov 2022
news & perspective View All

Lisocabtagene maraleucel obtains fda approval as a second-line treatment for rrLBCL

Lisocabtagene maraleucel (liso-cel), a cell-based gene therapy was approved as a second-line treatmentof relapsed or refractory (rr) large B-cell lymphoma (LBCL) in adult patients by the United States (US)Food and Drug Administration (FDA).1 Liso-cel is an autologous and chimeric antigen receptor T-cell (CAR-T)therapy that specifically directs cytotoxicity to CD19 antigen-presenting B cells.2,3 First approved inFebruary 2021, liso-cel treats certain types of LBCL, including diffuse LBCL (DLBCL), high-grade B-celllymphoma, primary mediastinal B-cell lymphoma, and follicular lymphoma grade 3B.2,3 Two new indicationshave been given to liso-cel for the LBCL treatment in patients who have refractory disease to thefirst-line immunochemotherapy, or refractory disease or relapse after the first-line immunochemotherapy.1,3The approval of liso-cel was supported by the TRANSFORM phase 3 study, which illustrated the efficacyand safety of the therapy as a second-line treatment for rrLBCL.1,3
03 Sep 2022

Phase 2 master trial: treatment with Dara-krd plus AHCT with NGS-MRD response-adapted therapy in NDMM patients

Combination therapy with proteasome inhibitors (PIs), monoclonal antibodies, immunomodulatory agents (IMiDs), dexamethasone plus autologous hematopoietic cell transplant (AHCT) may be an important course of treatment for newly diagnosed multiple myeloma (NDMM).1,2 However, predicting long-term outco
25 Feb 2022